Loading…
Swedish company developing and selling probiotic supplements and ingredients for infant, digestive and oral health.
Swedish company developing and selling probiotic supplements and ingredients for infant, digestive and oral health.
Sells its patented probiotic strains in two ways: as an ingredient for partners' branded products, and as its own drops and tablets through distributors in each country, mostly via pharmacies. Clinical studies on the strains are the sales tool, because doctors and pharmacists recommend products with evidence behind them.
In one line: A probiotics/consumer-health ingredient maker like a smaller International Flavors & Fragr.
Moat: narrow (IP / patents, brand). Patented, clinically studied probiotic strains licensed to global brands create a defensible ingredient niche.
Headquarters: Stockholm, Sweden · Founded: 1990 · Employees: 242
Size BioGaia (BIOG-B.ST) is a Sweden Health Care company (Pharmaceuticals: Other) with a market value of $1.26B, the 119th largest of 221 Sweden companies the cockpit tracks. Shares closed at SEK 122.10 on 6 Nov 2026.
Performance Over six months the shares fell 6.7%, against -13.0% for the median peer and +8.2% for the Sweden market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 13.1% over the last twelve months (peer median +4.6%); the operating margin is 28.2% (peer median 14.5%).
Valuation It trades at 30.1× forward earnings against a peer median of 17.7× (5th most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -15 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 47.7 points above its cost of capital (5.0% WACC).
Next results Next results expected around 12 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | SEK 1.65B | SEK 1.54B | SEK 1.42B | SEK 1.30B | SEK 1.10B |
| Revenue growth | — | +8% | +10% | +17% | — |
| Gross profit | SEK 1.20B | SEK 1.12B | SEK 1.02B | SEK 944M | SEK 797M |
| EBITDA | SEK 492M | SEK 477M | SEK 435M | SEK 464M | SEK 364M |
| Net income | SEK 392M | SEK 333M | SEK 351M | SEK 365M | SEK 374M |
| Free cash flow | SEK 258M | SEK 303M | SEK 359M | SEK 377M | SEK 301M |
| Capital expenditure | SEK 26.1M | SEK 3.60M | SEK 14.2M | SEK 48.7M | SEK 17.9M |
| Total debt | SEK 0 | SEK 6.90M | SEK 7.10M | SEK 8.80M | SEK 20.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| BioGaia BIOG-B.ST | $1.26B | -7% | +13% | 28% | 30.1× | 0.9% |
| Novo Nordisk A/S NOVO-B.CO | $190B | -7% | +6% | 48% | 11.9× | 0.1% |
| Danone BN.PA | $48.3B | +8% | 0% | 15% | 17.0× | -0.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BIOG-B.ST | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.8% | -0.2% | 6th highest of 21 |
| 6-month return | -6.7% | -13.0% | 9th highest of 21 |
| Distance from 52-week high | -10.4% | -27.7% | 5th highest of 21 |
| Revenue growth (TTM) | +13.1% | +4.6% | 10th highest of 21 |
| Operating margin | 28.2% | 14.5% | 3rd highest of 20 |
| Forward P/E | 30.1× | 17.7× | 5th most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 0.9% | 3.8% | 7th least demanding of 17 |
| Growth delivered (Del g) | +15.5% | +10.4% | 6th highest of 17 |
| Hurdle (Req g minus delivered) | -14.6 pp | -7.5 pp | 4th least demanding of 17 |
| ROIC minus cost of capital | +47.7 pp | +2.7 pp | highest of 20 |
| EV / EBITDA | 24.1× | 16.4× | 3rd most expensive of 10 |
| Net debt / EBITDA | -1.1× | 0.1× | 5th least indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| BioGaia BIOG-B.ST | Sweden | $1.26B | -7% | +13% | 28% | 30.1× | 0.9% | +15.5% |
| Pharma Mar PHM.MC | Spain | $1.30B | -33% | +32% | 19% | 37.7× | 11.4% | -3.9% |
| Cronos CRON.TO | Canada | $1.34B | +45% | +36% | -2% | 15.6× | 2.1% | +26.7% |
| HBM 2142.HK | Hong Kong | $1.18B | -23% | +55% | 44% | 12.4× | 14.1% | +62.3% |
| Jamieson Wellness JWEL.TO | Canada | $1.35B | +35% | +15% | 15% | 21.2× | 11.0% | +15.3% |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.41B | +75% | +27% | 33% | 67.7× | n/a | n/a |
| Shandong Xinhua Pharmaceutical 0719.HK | Hong Kong | $1.09B | -11% | -1% | 4% | 6.8× | -2.0% | +7.1% |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.53B | +27% | -3% | 24% | 18.6× | -2.2% | +5.5% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.55B | -2% | -6% | 15% | 14.2× | 4.5% | +60.2% |
| Applied Nutrition APN.L | United Kingdom | $1.01B | +42% | +24% | n/a | 24.2× | n/a | n/a |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $999M | -16% | -14% | 8% | 193.0× | n/a | n/a |
| Zhejiang Medicine 600216.SS | China | $1.61B | -23% | -6% | 7% | 11.3× | -6.7% | +3.9% |
| Tibet Cheezheng Tibetan Medicine 002287.SZ | China | $1.66B | -15% | -7% | 28% | n/a | -1.1% | +10.4% |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $952M | -35% | +30% | 15% | 9.7× | n/a | n/a |
| TSI 603262.SS | China | $909M | -41% | +3% | 14% | 51.5× | 25.8% | +13.4% |
| Porton Pharma Solutions 300363.SZ | China | $1.92B | +14% | +6% | -2% | n/a | 5.3% | +10.4% |
| PharmaNutra PHN.MI | Italy | $808M | -18% | +18% | 21% | 29.6× | 4.0% | +18.5% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $801M | -14% | -12% | 3% | n/a | 3.6% | -1.3% |
| China Meheco 600056.SS | China | $2.00B | -14% | +2% | 3% | n/a | -0.8% | -2.1% |
| Sirio Pharma 300791.SZ | China | $790M | -12% | -9% | 1% | 16.9× | 14.7% | +15.6% |
| Health and Happiness (H&H) International 1112.HK | Hong Kong | $2.05B | +70% | +24% | 16% | 12.6× | -3.0% | +4.4% |